Oxford BioMedica plc (OXB) Given “Hold” Rating at N+1 Singer
N+1 Singer reaffirmed their hold rating on shares of Oxford BioMedica plc (LON:OXB) in a research note issued to investors on Tuesday morning. The brokerage currently has a GBX 3.30 ($0.04) price objective on the biopharmaceutical company’s stock.
Separately, Jefferies Group began coverage on Oxford BioMedica plc in a research report on Friday, October 21st. They set a buy rating and a GBX 8 ($0.10) target price on the stock.
Oxford BioMedica plc (LON:OXB) opened at 3.515 on Tuesday. The stock’s 50 day moving average price is GBX 3.46 and its 200 day moving average price is GBX 4.15. Oxford BioMedica plc has a 52 week low of GBX 2.98 and a 52 week high of GBX 8.45. The firm’s market capitalization is GBX 93.67 million.
TRADEMARK VIOLATION NOTICE: “Oxford BioMedica plc (OXB) Given “Hold” Rating at N+1 Singer” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another website, it was stolen and republished in violation of US & international trademark and copyright law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2016/11/30/oxford-biomedica-plc-oxb-given-hold-rating-at-n1-singer.html.
In other news, insider Lorenzo Tallarigo purchased 75,417 shares of the business’s stock in a transaction on Friday, November 25th. The shares were bought at an average price of GBX 4 ($0.05) per share, with a total value of £3,016.68 ($3,742.31).
About Oxford BioMedica plc
Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.
Receive News & Stock Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related stocks with our FREE daily email newsletter.